European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Mainz Biomed Germany GmbH, Mainz, Germany (liq)

Watch
Mainz Biomed Germany GmbH

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier is a comprehensive company details as a PDF and publications in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Complete Dossier
Entire company details along with publications bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans
Risk report
Mainz Biomed Germany GmbH
Risk Level Evaluation Source
Sanctioned (?)

Name

Mainz Biomed Germany GmbH
PharmGenomics GmbH

Identification

Ut
District Court of Mainz HRB 41529
EUID
DET2304V.HRB41529

Address

Robert-Koch-Str. 50, 55129 Mainz, Germany

Corporate purpose

The development, production, distribution and application of in-vitro diagnostics and accompanying services

Financial performance

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
1Liquidator
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
One known shareholder
Portfolio and Investments
One known active shareholding
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Employee number
Revenue per employee
Cash on hand
Receivables
Liabilities
Total public funding
Number of public fundings
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
Financial Statements Interactive sheets with CSV/Excel download Premium
Premium
Balance
from 2008 to 2024
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

18 Jun 2026
Liq­ui­da­tion · Liquidator: Rolf Leithaus · No longer Managing Director: N.N. · Proxy policy
18 Jun 2026
Liq­ui­da­tion
24 Apr 2026
Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024
2 Oct 2025 in Sat
State Aid (€100,000 - €500,000): Germany - Evaluation plan for the block exempted R&D tax incentive scheme "Forschungszulagengesetz"
3 Jun 2025
Annual report for the year ending 31/12/2023 · Balance sheet for 31/12/2023
6 Sept 2024
Managing Director: N.N. · No longer Managing Director: Moritz Eidens, Philipp Freese
29 Dec 2023
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022
19 Dec 2022
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021
13 May 2022 via FIB Fonds für Innovation und Beschäftigung Rheinland-Pfalz Unternehmensbeteiligungsgesellschaft mbH also 17/12/2020, 31/01/2020, 05/07/2018, 26/07/2017
Shareholder: FIB Fonds für Innovation und Beschäftigung Rheinland-Pfalz Unternehmensbeteiligungsgesellschaft mbH
30 Mar 2022 via S-Innovations-Beteiligungsfinanzierungsgesellschaft Rheinland-Pfalz mbH also 09/02/2021, 05/02/2020, 09/08/2018, 27/07/2017
Shareholder: S-Innovations-Beteiligungsfinanzierungsgesellschaft Rheinland-Pfalz mbH (S-IFG)
27 Jan 2022 as PharmGenomics GmbH
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020
20 Jan 2022
Managing Director: Philipp Freese · No longer Authorized signatory (ppa) (1) · Share­holder agreement · Name: Mainz Biomed Germany GmbH · Corporate Purpose
14 Jan 2022
Original document: “Gesellschaftsvertrag / Satzung / Statut“
6 Jan 2022 as PharmGenomics GmbH
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019
23 Dec 2021
Original document: “Liste der Gesellschafter“
17 Dec 2021
Original document: “Liste der Gesellschafter“
25 Oct 2021
Original document: “Liste der Gesellschafter“
13 Sept 2021
Original document: “Liste der Gesellschafter“
8 Sept 2021 as PharmGenomics GmbH
Capital: €99,069 · Share­holder agreement
20 Aug 2021
Original document: “Liste der Gesellschafter“
20 Aug 2021
Original document: “Liste der Gesellschafter“
20 Aug 2021
Original document: “Liste der Gesellschafter“
20 Aug 2021
Original document: “Liste der Gesellschafter“
20 Aug 2021
Original document: “Liste der Gesellschafter“
20 Aug 2021 as PharmGenomics GmbH
Original document: “Liste der Gesellschafter“
20 Aug 2021
Original document: “Liste der Gesellschafter“
14 Jun 2021
Original document: “Liste der Gesellschafter“
8 Jun 2021
Original document: “Gesellschaftsvertrag / Satzung / Statut“
24 Nov 2020 as PharmGenomics GmbH
State Aid (€499,400): Modification and amendment to SA.56790, SA.59289, SA. 56814, SA.58504, SA.56787, SA.56863, SA.57100. SA.57447-Covid
9 Mar 2020 as PharmGenomics GmbH
Original document: “Liste der Gesellschafter“
18 Feb 2020 via Immundiagnostik AG also 22/02/2019
Shareholder: Immundiagnostik AG
12 Feb 2020 as PharmGenomics GmbH
Original document: “Liste der Gesellschafter“
10 Feb 2020 as PharmGenomics GmbH
Original document: “Liste der Gesellschafter“
1 Feb 2020 in Fk
Public funding (€426,595): Research into a multimarker test for the early detection of pancreatic cancer in the stool (PanCAlert) - Subproject: Prototype multimarker test using RT-PCR procedures
31 Jan 2020 as PharmGenomics GmbH
Original document: “Liste der Gesellschafter“
21 Nov 2019 as PharmGenomics GmbH
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018
14 Jan 2019 as PharmGenomics GmbH
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017
25 Jun 2018 as PharmGenomics GmbH
Original document: “Liste der Gesellschafter“
19 Jun 2018 as PharmGenomics GmbH
Capital: €92,584 · Share­holder agreement
9 Feb 2018 as PharmGenomics GmbH
Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016
30 Jan 2018
Original document: “Gesellschaftsvertrag / Satzung / Statut“
10 Nov 2017
Original document: “Liste der Gesellschafter“
1 Jan 2017 in Fk
Public funding (€292,440): Analysis platform for point-of-care testing of respiratory infections (RAPID-POCT) - Subproject: Development, establishment and validation of the RAPID-POCT system
22 Dec 2016 as PharmGenomics GmbH
Annual report for the year ending 31/12/2015 · Balance sheet for 31/12/2015
8 Dec 2015 as PharmGenomics GmbH
Capital: €55,552 · Share­holder agreement
8 Dec 2015 as PharmGenomics GmbH
Annual report for the year ending 31/12/2014 · Balance sheet for 31/12/2014
7 Dec 2015
Original document: “Gesellschaftsvertrag / Satzung / Statut“
10 Nov 2015
Original document: “Liste der Gesellschafter“
16 Mar 2015 as PharmGenomics GmbH
Managing Director: Philipp Freese · No longer Managing Director (1) · Share­holder agreement
3 Mar 2015
Original document: “Liste der Gesellschafter“
4 Feb 2015
Original document: “Gesellschaftsvertrag / Satzung / Statut“
5 Jan 2015 as PharmGenomics GmbH
Annual report for the year ending 31/12/2013 · Balance sheet for 31/12/2013
1 Aug 2014 in Fk
Public funding (€265,385): KMU-innovativ-13: Array-based rapid analysis of specific subspectra of the intestinal microflora as early disease indicators - MIDAS - , Subproject 2
12 Feb 2014 as PharmGenomics GmbH
Change of name or address: Wordmark: “HumaSense“
31 Jan 2014 as PharmGenomics GmbH
Annual report for the year ending 31/12/2012 · Balance sheet for 31/12/2012
17 Jan 2014 as PharmGenomics GmbH
Wordmark: “HumaSense“
19 Nov 2013 as PharmGenomics GmbH
Address
11 Nov 2013
Address
19 Aug 2013 as PharmGenomics GmbH
No longer Managing Director (1) · Capital: €41,664 · Share­holder agreement
5 Aug 2013
Capital: €41,664 · Share­holder agreement
29 May 2013
Original document: “Liste der Gesellschafter“
29 May 2013
Original document: “Gesellschaftsvertrag / Satzung / Statut“
30 Jul 2012 as PharmGenomics GmbH
Annual report for the year ending 31/12/2011 · Balance sheet for 31/12/2011
26 Jan 2011 as Pharmgenomics GmbH
Patent: Genotyping Cytochrome P450 2D6 (CYP2D6)
27 Dec 2010 as PharmGenomics GmbH
Annual report for the year ending 31/12/2009 · Balance sheet for 31/12/2009
1 Oct 2010 in Fk
Public funding (€356,523): ERA Net EuroTransBio-5: Development of a novel CYP macroarray to assess patient-specific susceptibility to pharmacological agents - CYPchip, TV: Development & validation of …
17 Feb 2010 as PharmGenomics GmbH
Authorized signatory (ppa) (1) · Share­holder agreement
9 Feb 2010
Authorized signatory (ppa) (1) · Capital: €27,800 · Share­holder agreement
28 Jan 2010
Original document: “Liste der Gesellschafter“
28 Jan 2010
Original document: “Liste der Gesellschafter“
15 Jan 2010
Original document: “Gesellschaftsvertrag / Satzung / Statut“
11 Dec 2009 as Pharmgenomics GmbH
Patent: Genotyping Dihydropyrimidine Dehydrogenase Deficiency
30 Oct 2009
Corrigendum: Registered ex officio in accordance with Article 65 sentence 3 EGHGB: Business address: Parcusstraße 8 …
30 Oct 2009 as PharmGenomics GmbH
Annual report for the year ending 31/12/2008 · Balance sheet for 31/12/2008
27 Oct 2009
Registered ex officio in accordance with Article 65 sentence 3 EGHGB: Business address: Parcusstraße 9, 55116 Mainz
1 Aug 2008 as PharmGenomics GmbH
Reg­is­tra­tion · Managing Director (3) · Capital: €25,000 · Share­holder agreement · Proxy policy · Corporate Purpose
21 Jul 2008 as PharmGenomics GmbH
Reg­is­tra­tion · Managing Director (3) · Capital: €25,000 · Seat: Mainz · Legal form: GmbH · Name: PharmGenomics GmbH · Corporate Purpose
24 Jun 2008
Original document: “Liste der Gesellschafter“
24 Jun 2008
Original document: “Liste der Gesellschafter“
11 Jun 2008
Original document: “Liste der Gesellschafter“
11 Jun 2008
Original document: “Liste der Gesellschafter“
11 Jun 2008
Original document: “Gesellschaftsvertrag / Satzung / Statut“
There are no publications matching your search.

Mentions

28 Mar 2025 in Hrcdd
No longer Control, No longer Profit Transfer: European Oncology Lab GmbH
18 Sept 2024 in Hrdk also 14/08/2023, 05/06/2023
European Oncology Lab GmbH: “Liste der Gesellschafter“
17 May 2024 in Hrcdd
Control, Profit Transfer: European Oncology Lab GmbH
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.